Mutual of America Capital Management LLC Has $311,000 Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Mutual of America Capital Management LLC cut its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 11.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,537 shares of the company’s stock after selling 968 shares during the period. Mutual of America Capital Management LLC’s holdings in Inari Medical were worth $311,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of NARI. KBC Group NV raised its stake in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares during the period. Aigen Investment Management LP acquired a new stake in Inari Medical during the third quarter worth about $428,000. Versor Investments LP acquired a new position in Inari Medical during the third quarter valued at approximately $396,000. State of New Jersey Common Pension Fund D boosted its stake in Inari Medical by 23.7% in the third quarter. State of New Jersey Common Pension Fund D now owns 46,087 shares of the company’s stock valued at $1,901,000 after buying an additional 8,830 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after purchasing an additional 926 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Insider Activity at Inari Medical

In other news, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the completion of the transaction, the director now owns 501,233 shares of the company’s stock, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 186,000 shares of company stock worth $8,990,990. 10.60% of the stock is owned by corporate insiders.

Inari Medical Stock Performance

Shares of NARI opened at $51.03 on Friday. The firm has a market cap of $2.99 billion, a P/E ratio of -37.80 and a beta of 0.96. The business has a 50-day moving average of $46.00 and a 200 day moving average of $47.45. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $67.13.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on NARI. Leerink Partnrs upgraded Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Robert W. Baird lifted their price objective on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Piper Sandler increased their price target on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday, October 29th. Canaccord Genuity Group upped their target price on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $58.89.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.